TP53 and gastric adenocarcinoma: Significantly, our recent analysis of The Cancer Genome Atlas (TCGA) demonstrated that TP53 is an attractive target for patients with ovarian serous cystadenocarcinoma (OV) and stomach adenocarcinoma (STAD) through its action as a master regulator of macrophage polarization and infiltration (1).